scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.AMJMED.2017.12.010 |
P698 | PubMed publication ID | 29284111 |
P2093 | author name string | David van Klaveren | |
David M Kent | |||
Marvin A Konstam | |||
Jenica N Upshaw | |||
P2860 | cites work | The effect of digoxin on mortality and morbidity in patients with heart failure | Q73080377 |
An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase | Q74499672 | ||
Clinical benefits of low serum digoxin concentrations in heart failure | Q77772125 | ||
Heart Disease and Stroke Statistics--2015 Update: A Report From the American Heart Association | Q22241921 | ||
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal | Q24288920 | ||
Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data | Q26796271 | ||
Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials | Q31112168 | ||
Evaluating the yield of medical tests | Q34277948 | ||
Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial | Q34647669 | ||
Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program. | Q35158163 | ||
Estimating treatment effects for individual patients based on the results of randomised clinical trials | Q35252544 | ||
Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis | Q35752516 | ||
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial | Q37066497 | ||
Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association | Q37538031 | ||
Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction: Model Derivation and External Validation | Q38388968 | ||
Rehospitalizations among patients in the Medicare fee-for-service program | Q39513280 | ||
Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm | Q40832107 | ||
Aggregating and disaggregating patients in clinical trials and their subgroup analyses | Q42417534 | ||
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial | Q43239377 | ||
The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models. | Q51714177 | ||
Heart failure in outpatients: a randomized trial of digoxin versus placebo | Q70221207 | ||
Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study | Q70746802 | ||
Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure | Q71297666 | ||
Association of serum digoxin concentration and outcomes in patients with heart failure | Q73004928 | ||
P407 | language of work or name | English | Q1860 |
P921 | main subject | heart failure | Q181754 |
digoxin | Q422222 | ||
hospitalization | Q3140971 | ||
P577 | publication date | 2017-12-25 | |
P1433 | published in | American Journal of Medicine | Q2842959 |
P1476 | title | Digoxin Benefit Varies by Risk of Heart Failure Hospitalization: Applying the Tufts MC HF Risk Model. |
Q89304755 | Pharmacologic Management of Cancer Therapeutics-Induced Cardiomyopathy in Adult Cancer Survivors | cites work | P2860 |
Search more.